clinic
practic
initi
therapeut
approach
cat
suspect
retrovir
infect
alway
support
symptomat
diagnosi
retrovir
infect
establish
antivir
immun
modul
consid
short
longterm
manag
take
account
drug
licens
use
human
lack
wellcontrol
clinic
trial
cat
efficaci
entir
clear
nowaday
antivir
licens
use
veterinari
medicin
except
sever
immun
modul
concurr
antivir
properti
therefor
truli
antivir
compound
use
dog
cat
licens
use
human
name
hiv
therapi
hand
interestingli
administr
antivir
cat
frequent
document
due
fact
fivinfect
cat
commonli
use
hiv
experiment
model
even
antivir
shown
low
efficaci
cat
induc
signific
toxic
effect
sever
use
manag
retrovir
infect
among
rt
inhibitorsnucleosid
analogu
common
major
nucleosid
analogu
act
antimetabolit
fals
substrat
bind
rt
enzym
block
activ
antivir
use
retrovir
infect
antagonistshomolog
receptor
name
byciclam
plerixafor
amd
bind
either
virus
homolog
cellreceptor
antagonist
inhibit
interact
except
sever
drug
compound
strongli
select
hiv
mean
use
veterinari
medicin
take
part
group
immun
therapi
definit
immun
modul
compound
interfer
immun
system
commonli
use
differ
clinic
situat
particularli
canin
felin
viral
infect
believ
immun
modul
restor
sever
function
immun
system
allow
better
manag
opportunist
infect
better
clinic
recoveri
compound
even
direct
antivir
effect
wellknown
immun
modul
interferon
ifn
discuss
mainli
due
current
use
retrovir
infect
interferon
ifn
key
compon
host
immun
system
particularli
relev
viral
infect
larg
famili
ifn
divid
differ
type
type
ifn
studi
one
commonli
use
therapeut
purpos
among
major
function
type
ifn
increas
sensit
immun
system
toward
microbi
recognit
establish
import
link
innat
acquir
immun
furthermor
differ
antivir
properti
block
viral
replic
induc
apoptosi
infect
cell
human
immunodefici
viru
hiv
therapeut
use
ifn
assess
variou
vitro
vivo
studi
vitro
proven
ifn
abl
restrict
hiv
replic
induc
antivir
state
prevent
viral
infect
vivo
despit
hiv
evas
mechan
ifn
seem
play
import
protect
role
hiv
infect
seroneg
individu
expos
viru
moreov
therapeut
administr
show
durabl
suppress
viral
replic
decreas
viral
integr
follow
antiretrovir
therapi
hiv
individu
even
studi
need
investig
therapeut
effect
ifn
hiv
protect
role
earli
stage
infect
aim
consid
ifn
therapi
seem
particularli
use
postexposur
prophylaxi
human
also
felin
medicin
use
type
ifn
immun
modul
therapi
common
particularli
retrovir
infect
still
use
sever
countri
first
interferon
administ
cat
despit
fact
licens
human
medicin
among
major
function
shown
inhibit
oncogen
mutat
induc
retrovirus
restrain
viral
nucleic
acid
synthesi
suppress
protein
product
due
antivir
immun
modul
properti
use
variou
human
diseas
myeloid
leukemia
papilomatosi
hiv
reason
also
use
felin
medicin
name
fiv
felv
fcv
fcov
viral
infect
spite
shortterm
effect
particularli
clinic
improv
increas
surviv
time
develop
neutral
antibodi
sever
week
therapi
make
ineffect
longterm
immun
modul
therapi
cat
problem
bypass
recent
releas
recombin
felin
interferon
omega
first
interferon
compound
licens
use
veterinari
medicin
specif
cat
product
approv
use
retrovir
infect
name
felin
immunodefici
viru
fiv
felin
leukemia
viru
felv
accord
manufactur
instruct
licens
administ
three
cycl
five
daili
subcutan
inject
mukg
begin
respect
day
despit
fact
licens
year
ago
studi
support
clinic
benefit
particularli
retrovir
infect
first
studi
describ
clinic
applic
date
report
treat
felin
leukemia
viru
felv
fivfelv
coinfect
cat
show
signific
clinic
improv
increas
surviv
time
recent
anoth
research
group
reinforc
improv
clinic
sign
hematolog
paramet
retrovir
infect
cat
howev
accord
studi
chang
hypergammaglobulinemia
provir
load
viremia
suggest
overal
effect
mainli
innat
immun
reaction
rather
acquir
immun
mean
seem
antivir
effect
vivo
observ
clinic
improv
must
relat
potenti
immun
modul
innat
immun
system
moreov
contrast
vitro
studi
antivir
vivo
action
licens
protocol
toward
fiv
felv
found
neglig
accord
author
point
highlight
need
studi
order
clarifi
mechan
action
author
tri
extend
current
knowledg
compound
order
support
clarifi
evid
clinic
improv
previous
describ
experiment
work
reli
two
distinct
clinic
trial
one
refer
retrovir
infect
cat
fiv
felv
coinfect
cat
treat
licens
subcutan
protocol
describ
altern
oral
protocol
administ
fivinfect
cat
protocol
compar
immunolog
virolog
perspect
firstli
effect
licens
protocol
cat
live
anim
shelter
evalu
assess
clinic
improv
monitor
concurr
viral
excret
name
herpesviru
caliciviru
coronaviru
previou
studi
cat
treat
document
induc
clinic
improv
could
potenti
relat
recoveri
seriou
opportunist
infect
order
assess
whether
properti
differ
hematolog
biochemistri
paramet
monitor
scorescal
system
allow
evalu
clinic
improv
treat
cat
valid
agreement
two
previou
refer
studi
signific
clinic
improv
treat
anim
without
relev
chang
hematolog
biochemistri
profil
report
concern
result
seem
abl
contribut
manag
realiti
improv
clinic
sign
decreas
concurr
viral
excret
therefor
must
consid
effect
immunemodul
therapi
use
shelter
medicin
preval
concomit
infect
higher
studi
influenc
acut
phase
reaction
investig
human
medicin
sever
studi
describ
increas
hivposit
patient
even
immunomodul
therapi
exogen
despit
similar
hiv
fiv
crp
behavior
fivposit
cat
undergo
immunemodul
therapi
remain
unknown
follow
previou
conclus
suggest
compound
act
innat
respons
rather
acquir
immun
system
effect
acut
phase
protein
app
evalu
take
account
app
one
key
compon
innat
immun
system
seem
reason
predictor
innat
immunestimul
author
show
app
significantli
increas
cat
treat
licens
protocol
despit
fact
app
usual
increas
differ
situat
chronic
infect
sever
inflamm
studi
increment
concomit
describ
clinic
improv
reduct
opportunist
infect
work
show
app
increment
might
benefici
retrovir
infect
cat
confirm
reason
indic
potenti
innat
immun
respons
first
work
document
effect
app
profil
studi
reinforc
action
compound
innat
immun
system
help
clarifi
mechan
action
licens
protocol
order
explor
greater
detail
conclus
evalu
innat
immun
biomark
name
mx
protein
would
use
although
use
felin
medicin
scarc
mx
protein
specif
type
ifn
biomark
henc
product
directli
relat
activ
type
ifn
signal
transduct
pathway
sens
author
point
view
studi
need
strengthen
conclus
assess
whether
mx
protein
reason
biomark
innat
immun
cat
therapi
recogn
clinic
practic
often
costlimit
therapi
use
altern
oral
protocol
fivinfect
cat
also
document
fact
differ
author
report
clinic
benefit
oral
low
dose
protocol
viral
infect
fiv
releas
sever
clinic
trial
also
conduct
specificpathogen
free
cat
calicivirusposit
cat
order
studi
immunemodul
properti
oral
howev
studi
document
use
retrovir
infect
cat
particularli
fivinfect
one
sens
oral
protocol
develop
administ
clientown
fivinfect
cat
oral
dose
base
refer
previou
studi
decid
accord
manufactur
previou
trial
oral
protocol
lower
licens
subcutan
protocol
given
oral
instead
subcutan
longer
period
time
continu
day
follow
methodolog
previou
studi
clinic
improv
concurr
viral
excret
app
profil
differ
hematolog
biochemistri
paramet
fivinfect
cat
treat
oral
protocol
assess
similarli
observ
licens
protocol
cat
treat
oral
show
signific
clinic
improv
without
remark
chang
hematolog
biochemistri
profil
within
refer
rang
major
treat
cat
convers
mainli
due
fact
clientown
cat
less
prone
opportunist
infect
concurr
viral
excret
low
chang
appli
protocol
addit
app
profil
chang
cat
treat
oral
mean
two
distinct
protocol
seem
act
differ
take
app
biomark
innat
immun
respons
seem
reason
say
innat
immun
reaction
seem
potenti
way
observ
licens
protocol
howev
interferon
pleotrop
effect
app
part
innat
immun
respons
overspecul
assum
oral
interfer
innat
immun
even
app
chang
overal
result
show
import
clinic
improv
reinforc
potenti
extralabel
use
oral
continu
lowdos
protocol
second
time
effect
protocol
cytokin
profil
viremia
provir
load
evalu
one
studi
previous
report
licens
protocol
chang
viremia
provir
load
treat
fivinfect
cat
suggest
compound
may
act
acquir
immun
agreement
result
author
conclud
viremia
chang
group
fivinfect
cat
treat
licens
protocol
howev
opposit
previous
report
signific
increas
provir
load
report
correl
rel
increas
lymphocyt
cell
count
even
within
normal
rang
studi
viremia
provir
load
chang
fivinfect
cat
treat
oral
also
evalu
expect
chang
obtain
either
paramet
reinforc
previou
suggest
independ
administ
protocol
antivir
effect
vivo
neglig
point
conclud
licens
protocol
induc
decreas
concurr
viral
infect
even
true
chang
fiv
viral
load
hand
oral
protocol
albeit
chang
viral
load
concurr
viral
infect
signific
clinic
improv
treat
cat
therefor
even
antivir
properti
fiv
seem
neglig
protocol
fact
decreas
concurr
viral
infect
cat
treat
licens
protocol
rais
question
whether
true
antivir
effect
toward
virus
whether
result
overal
stimul
innat
acquir
immun
system
author
point
view
overspecul
state
act
acquir
immun
system
base
viremia
provir
load
therefor
evalu
cytokin
profil
anim
seem
essenti
fulli
understand
action
order
reinforc
previou
suggest
affect
acquir
immun
system
fivinfect
cat
mrna
express
concurr
plasma
level
variou
cytokin
monitor
use
biolog
sampl
two
group
fivinfect
cat
treat
either
subcutan
oral
protocol
despit
pleiotrop
effect
variat
respons
assess
base
differ
measur
cytokin
result
show
respons
significantli
chang
either
protocol
support
previou
suggest
strongli
affect
acquir
immun
system
among
measur
cytokin
proinflammatori
cytokin
involv
differ
immun
pathway
particularli
innat
immun
respons
significantli
chang
group
fact
cat
treat
licens
protocol
plasma
level
significantli
reduc
whilst
respect
mrna
express
show
decreas
tendenc
statist
signific
hand
cat
treat
oral
plasma
level
chang
concurr
mrna
express
significantli
decreas
document
product
affect
protocol
mean
antiinflammatori
properti
moreov
consid
plasma
chang
signific
cat
treat
licens
protocol
seem
reason
state
higher
pulsat
therapeut
scheme
effici
reduc
proinflammatori
stimuli
continu
low
dose
therapi
first
studi
explor
effect
differ
biomark
immun
system
howev
still
mani
point
investig
order
explor
whole
potenti
compound
retrovir
infect
fivinfect
cat
two
protocol
assess
follow
research
line
would
interest
reinforc
conclus
pharmacokinet
pharmacodynam
studi
subcutan
protocol
would
use
document
effect
lower
dose
longer
therapi
cycl
viceversa
order
correl
therapi
requir
clinic
virolog
condit
oral
group
would
also
interest
assess
effect
intermedi
higher
dose
shorter
period
also
extend
protocol
felvinfect
cat
spite
differ
physiopatholog
aggress
clinic
portrait
would
interest
assess
effect
suggest
oral
anim
accord
author
point
view
unlik
lower
oral
dose
effect
clinic
improv
felvinfect
cat
sinc
anim
usual
symptomat
wors
overal
clinic
condit
fivinfect
anim
consequ
higher
subcutan
protocol
alway
prefer
cat
previous
state
sever
studi
shown
ifn
benefici
earli
stage
hiv
infect
recogn
result
concern
natur
infect
cat
time
infect
unknown
find
way
agreement
hiv
studi
indirectli
reflect
innat
immunemodul
decreas
clinic
sign
coinfect
compar
explor
full
potenti
rout
dose
would
interest
studi
combin
protocol
use
accord
differ
clinic
present
although
studi
assess
possibl
combin
protocol
think
reason
associ
therapi
well
document
show
import
advers
effect
instanc
symptomat
anim
initi
subcutan
protocol
follow
oral
continu
lowerdos
therapi
recommend
author
point
view
seem
reason
approach
sooner
later
consid
routin
clinic
practic
also
regard
followup
life
span
studi
warrant
fact
author
tri
perform
monthli
trimest
followup
end
therapi
group
unsuccess
anim
shelter
clinic
evalu
therapi
unreason
incom
outcom
cat
impair
correct
conclus
regard
clientown
cat
correctli
achiev
small
number
treat
anim
unpublish
data
fact
individu
oral
therapi
cat
free
charg
compris
total
daili
dose
partial
given
owner
evalu
time
point
end
therapi
monitor
unpract
major
owner
unavail
pursuit
monthli
followup
consequ
structur
prospect
studi
would
interest
order
evalu
longterm
benefit
therapi
also
effect
mean
life
span
fivinfect
cat
studi
innov
extens
main
therapeut
properti
licens
protocol
natur
retrovir
infect
cat
document
must
use
clientown
symptomat
cat
also
anim
live
catteri
shelter
opportunist
infect
problemat
although
without
truli
effect
cytokin
profil
compound
induc
signific
clinic
improv
seem
reduc
proinflammatori
stimuli
particularli
fivinfect
cat
work
present
new
oral
protocol
success
test
valid
although
induc
signific
clinic
improv
overal
action
immun
modul
less
subcutan
protocol
fact
slightli
decreas
proinflammatori
stimuli
without
affect
acquir
immun
even
paramet
innat
respons
acut
phase
protein
therefor
whilst
high
pulsat
subcutan
protocol
strongli
recommend
symptomat
fivinfect
cat
lower
continu
oral
protocol
good
altern
cat
present
mild
clinic
sign
case
cost
limit
use
licens
protocol
even
cat
previous
receiv
subcutan
requir
continu
immun
modul
therapi
studi
contribut
better
understand
much
explor
immun
modul
properti
valid
new
oral
protocol
includ
futur
fivguidelin
summari
review
reinforc
benefici
properti
ifn
therapi
open
new
perspect
use
retrovir
infect
even
speciesspecif
compound
conclus
extrapol
larger
perspect
either
fivinfect
cat
hiv
individu
type
ifn
seem
induc
innat
immunemodul
overlook
therapeut
option
retrovir
infect
